202 completed, 19 recruiting, 18 terminated, 18 unknown. 292 Phase 1, 70 Phase 2.
Follow Depressive Disorder: new trials by email Literature Review of Depressive Disorder trials Research Report on Depressive Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder Psilocybin - Treatment Resistant Depression, Substance Use Disorders | Phase 1 / Phase 2 | Not yet recruiting | Indiana University | 50 | 2027-02-01 | 2026-10-23 |
| A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients PDC-1421 Capsule - Major Depressive Disorder | Phase 1 / Phase 2 | Not yet recruiting | BioLite, Inc. | 12 | 2027-01-15 | 2026-04-20 |
| MLS101 Study in PMDD MLS101 psilocybin, Placebo capsules - Premenstrual Dysphoric Disorder ( PMDD), PMDD | Phase 1 | Not yet recruiting | MycoMedica Life Sciences PBC | 32 | 2026-12-01 | 2026-09-14 |
| Shortened LSD Intervention for Major Depressive Disorder LSD, Risperidone - Major Depression Moderate, Major Depression Severe | Phase 1 | Not yet recruiting | Johns Hopkins University | 10 | 2026-10-01 | 2026-09-22 |
| Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder Sham iTBS, TMS, D-cycloserine - Major Depression, Healthy Participants | Phase 1 / Phase 2 | Not yet recruiting | Mclean Hospital | 100 | 2026-09-01 | 2026-08-14 |
| Pregnenolone for Cannabis Use Disorder and Depression Pregnenolone - Cannabis Use Disorder, Major Depressive Disorder (MDD) | Phase 1 / Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 20 | 2026-09-01 | 2026-07-06 |
| A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects Selegiline Transdermal Delivery System - Major Depressive Disorder (MDD) | Phase 1 | Active not recruiting | Corium Innovations, Inc. | 232 | 2026-08-23 | 2026-08-31 |
| Cannabidiol Oil for Treatment-Resistant Major Depression Full-spectrum CBD oil 100 mg/mL, Placebo oil (MCT oil) - Major Depressive Disorder (MDD), Treatment-resistant Depression (TRD) | Phase 1 / Phase 2 | Recruiting | Universidade do Sul de Santa Catarina | 120 | 2026-06-01 | 2026-07-10 |
| Pattern Separation in Major Depressive Disorder SSRI (escitalopram or sertraline), Extended-Release Memantine, Placebo - Major Depressive Disorder (MDD) | Phase 1 | Recruiting | Jeffrey Miller | 30 | 2026-06-01 | 2026-09-15 |
| First-In-Human (FIH), Single Ascending Dose (SAD) Study and Multiple Ascending Dose (MAD) Study of SP-101 Injection SP-101 injection, Placebo - Major Depressive Disorder, Healthy Volunteer | Phase 1 | Not yet recruiting | Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd. | 80 | 2025-12-23 | 2026-01-12 |
| Ketamine Biomarker Validation Ketamine (0.25 mg/kg), Ketamine (0.5 mg/kg), Ketamine (0.75 mg/kg) - Treatment Resistant Depression (TRD) | Phase 1 | Withdrawn | Soterix Medical | 2025-12-20 | 2026-10-19 | |
| Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL) Ketamine, Cognitive Behavioural Therapy - Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD) | Phase 1 / Phase 2 | Not yet recruiting | South West Sydney Local Health District | 20 | 2025-12-10 | 2025-11-25 |
| To Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Food Effects of LY03021 in Healthy Chinese Subjects LY03021, placebo - Major Depressive Disorder | Phase 1 | Enrolling by invitation | Luye Pharma Group Ltd. | 98 | 2025-10-28 | 2026-01-27 |
| Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine Cariprazine Depot, Cariprazine Depot MTD, Oral Cariprazine 3 mg/day - Schizophrenia, Bipolar I Disorder | Phase 1 / Phase 2 | Recruiting | Mapi Pharma Ltd. | 24 | 2025-08-01 | 2026-05-01 |
| Magnetic Resonance-Guided Focused Ultrasound Bilateral Capsulotomy for Refractory Anorexia Nervosa With Comorbid Obsessive Compulsive Disorder or Major Depressive Disorder ExAblate Neuro 4000 - Anorexia Nervosa (DSM-IV Revised Criteria) | Phase 1 | Recruiting | Sunnybrook Health Sciences Centre | 10 | 2025-08-01 | 2025-08-14 |
| Theta-Burst Stimulation to Treat Depression Spaced iTBS, Compressed iTBS - Major Depressive Disorder (MDD) | Phase 1 | Recruiting | Centre for Addiction and Mental Health | 84 | 2025-06-01 | 2025-06-24 |
| Repeated Neurocognitive Measurements in Depressed Patients Intravenous Ketamine - Depression, Unipolar | Phase 1 / Phase 2 | Withdrawn | Jay Fournier | 2025-05-01 | 2026-02-25 | |
| Multiple Ascending Dose Phase 1 Study of ALA-3000 ALA-3000, Placebo, escitalopram, sertraline, duloxetine or venlafaxine XR - Treatment Resistant Depression | Phase 1 | Completed | Alar Pharmaceuticals Inc. | 37 | 2025-04-21 | 2025-12-31 |
| Prevention of Postpartum Depression: A Pilot Placebo-controlled Trial of Trazodone Trazodone, Placebo - Postpartum Depression | Phase 1 | Withdrawn | Verinder Sharma | 2025-04-17 | 2025-04-04 | |
| Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery Ketamine (Ketalar) - Pain, Postpartum Depression | Phase 1 | Recruiting | University of Utah | 50 | 2025-03-28 | 2026-10-02 |
Showing 20 of 292. Sign in to see all of them.
Depressive Disorder, Major (211) · Depression (81) · Depressive Disorder, Treatment-Resistant (34) · Anxiety Disorders (17) · Mood Disorders (15) · Stress Disorders, Post-Traumatic (14) · Bipolar Disorder (13) · Depression, Postpartum (10) · Mental Disorders (9) · Dysthymic Disorder (6) · Schizophrenia (6) · Generalized Anxiety Disorder (4) · Obsessive-Compulsive Disorder (4) · Panic Disorder (4)
Mental Disorders (283) · Mood Disorders (277) · Behavior (83) · Behavioral Symptoms (80) · Trauma and Stressor Related Disorders (16) · Bipolar and Related Disorders (13) · Stress Disorders, Traumatic (12) · Pathological Conditions, Signs and Symptoms (11) · Female Urogenital Diseases and Pregnancy Complications (10) · Pregnancy Complications (10) · Puerperal Disorders (10) · Urogenital Diseases (10) · Nervous System Diseases (9) · Chemically-Induced Disorders (7)
Ketamine (25) · alpha-((5-fluoro-2-methoxyphenyl)methyl)-alpha-(tetrahydro-2H-pyran-4-yl)-2-morpholinemethanol (16) · Escitalopram (8) · Cognitive Behavioral Therapy (6) · Desvenlafaxine Succinate (6) · Psilocybin (6) · Sertraline (6) · Citalopram (5) · Therapeutics (5) · Transcranial Magnetic Stimulation (5) · seltorexant (5) · Fluoxetine (4) · Paroxetine (4) · Saline Solution (4) · Sodium Chloride (4)
GlaxoSmithKline (27) · Eli Lilly and Company (17) · National Institute of Mental Health (NIMH) (9) · Luye Pharma Group Ltd. (8) · Janssen Research & Development, LLC (7) · Mclean Hospital (7) · Washington University School of Medicine (6) · University of California, Los Angeles (5) · Centre for Addiction and Mental Health (4) · Sadat City University (4) · Sunnybrook Health Sciences Centre (4) · Syndeio Biosciences, Inc (4) · Yale University (4) · Butler Hospital (3) · Laureate Institute for Brain Research, Inc. (3)
United States (150) · United Kingdom (26) · China (20) · Canada (19) · Germany (16) · Australia (9) · Netherlands (8) · Belgium (6) · Brazil (6) · Egypt (4) · India (4) · Israel (4) · Japan (4) · Austria (2) · Bulgaria (2)
Carlos A Zarate, M.D. (3) · Amy Sun, MD, PhD, MBA (2) · Catherine Harmer (2) · Charles R Conway, MD (2) · Diego A Pizzagalli, PhD (2) · Fabian Devlin, MD (2) · Grace Lim, MD, MSc (2) · John Krystal, MD (2)
PMID 25150403, PMID 31784354, PMID 32241310, PMID 35963959, PMID 40484114, PMID 14702256, PMID 15780843, PMID 16319710, PMID 16585452, PMID 16894061, PMID 17429407, PMID 18061147, PMID 18996507, PMID 19545857, PMID 19744406, PMID 19897179, PMID 19914605, PMID 19995444, PMID 20673547, PMID 20679587, PMID 21450159, PMID 21459988, PMID 21731830, PMID 21736514, PMID 22065593, PMID 22125120, PMID 22296967, PMID 22297150, PMID 22409700, PMID 22473055, PMID 22521148, PMID 22570264, PMID 22722512, PMID 22945620, PMID 23300127, PMID 23482332, PMID 23562618, PMID 23685546, PMID 23773978, PMID 23805231, PMID 23916389, PMID 23990896, PMID 24191345, PMID 24462229, PMID 24643964, PMID 25054988, PMID 25169854, PMID 25271445, PMID 25295436, PMID 25400146
2016 (3), 2015 (2), 2017 (2), R01MH134538 (2), 1UG3DA066242-01 (1), 2014 (1), 2018 (1), 2019 (1), K01DA029645 (1), K23MH064528 (1), K23MH074860 (1), K24MH102743 (1), P20MH090318 (1), R01AA024933 (1), R01MH068376 (1)